Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Organon & Co. OGN

Healthcare — Drug Manufacturers General
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.50
Total sells
0.55
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — 1 — — — — — — — — — —
Sell — — — — — — — 1 — — 1 —
Insider Ownership
0.64%

Capital & Financial Ratios

Market Cap
3,600.00
Revenue
6,127.00
Net Income
209.00
Free Cash Flow
464.00
Net Debt
7,421.00
Current Ratio
1.95
Debt/Equity
8.50
P/E ratio
17.32
P/S ratio
0.59
P/B ratio
3.57
Past 5Y EPS Growth
(23.49%)
This Y EPS Growth
(8.47%)
Next Y EPS Growth
8.36%
Next 5Y EPS Growth
3.09%
in millions of $

Dividends

Payout Ratio
0.38
Annual Dividend Rate
1.12
Annual Dividend Yield
6.88%
total individual payouts
2028 ‡‡‡‡
2027 ‡‡‡‡‡
2026 0.08
—
—
—
2025 0.34
—
—
—
—
2024 1.12
—
—
—
—
2023 1.12
—
—
—
—
2022 1.12
—
—
—
—
2021 0.56
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 693.00 675.00 574.00 1,132.00
Receivables 1,744.00 1,358.00 1,331.00 1,492.00
Inventory 1,315.00 1,321.00 1,406.00 1,351.00
Other 756.00 994.00 1,041.00 1,136.00
4,508.00 4,348.00 4,352.00 5,111.00
2023 2024 2025 Q'26
Payables 1,314.00 1,153.00 952.00 1,051.00
ST’ Debt 9.00 20.00 16.00 74.00
Other — — 2.00 —
2,918.00 2,718.00 2,390.00 2,616.00
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡‡‡ ‡‡‡‡‡
Earnings — ‡‡‡‡‡ ‡‡‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 1,460.00 1,558.00 — —
—
’25 1,513.00 1,594.00 1,602.00 1,507.00
6,216.00
’24 1,622.00 1,607.00 1,582.00 1,592.00
6,403.00
’23 1,538.00 1,608.00 1,519.00 1,598.00
6,263.00
’22 1,567.00 1,585.00 1,537.00 1,485.00
6,174.00
’21 1,506.00 1,595.00 1,600.00 1,603.00
6,304.00
’20 1,780.00 1,526.00 1,613.00 1,613.00
6,532.00
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 225.00 107.00 — —
—
’25 75.00 220.00 264.00 141.00
700.00
’24 76.00 332.00 141.00 390.00
939.00
’23 114.00 27.00 261.00 397.00
799.00
’22 123.00 151.00 317.00 267.00
858.00
’21 1,300.00 445.00 368.00 47.00
2,160.00
’20 747.00 733.00 320.00 387.00
2,284.00
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 188.00 31.00 — —
—
’25 (12.00) 182.00 149.00 96.00
415.00
’24 (20.00) 301.00 77.00 305.00
663.00
’23 68.00 (43.00) 206.00 316.00
547.00
’22 60.00 68.00 209.00 208.00
545.00
’21 1,262.00 388.00 140.00 (7.00)
1,783.00
’20 708.00 686.00 275.00 260.00
2,034.00
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.55 0.40 — —
—
’25 0.33 0.56 0.61 (0.79)
0.72
’24 0.78 0.75 1.38 0.42
3.33
’23 0.69 0.95 0.23 2.13
3.99
’22 1.36 0.92 0.89 0.42
3.59
’21 1.58 1.68 1.27 0.79
5.31
’20 — — 2.16 1.45
8.52

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — — ‡‡‡‡‡ 22.88 10.84 13.65 6.18 — — —
Low Price
— — — — — ‡‡‡‡‡ 39.48 32.43 23.10 17.23 — — —
High Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 10,000 10,000 4,000 10,000 — — —
Employees
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.62 0.63 1.60 0.62 — — —
Revenue/Emp
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6,174.00 6,263.00 6,403.00 6,216.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 62.84% 59.84% 58.02% 53.30% — — —
Gross Margin
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,122.00 673.00 807.00 425.00 — — —
EBT
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 18.17% 10.75% 12.60% 6.84% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 917.00 1,023.00 864.00 187.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 212.00 236.00 288.00 612.00 — — —
Depreciation
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 24.30 24.54 24.91 23.95 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 3.61 4.01 3.36 0.72 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
Earnings/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.38 3.13 3.65 2.70 ‡‡‡‡ — —
Cash Flow/Sh
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.23) (0.99) (1.07) (1.10) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.15 2.14 2.58 1.60 — — —
Free CF/Sh
— ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.51) (0.27) 1.84 2.90 ‡‡‡ — —
Book Value/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 254.08 255.24 257.05 259.50 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.80 3.66 4.45 9.96 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.16 0.60 0.60 0.30 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00 0.00 8.13 2.47 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.48 1.89 1.88 1.60 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 28.15 26.10 18.16 23.93 — — —
EV/FCF
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 858.00 799.00 939.00 700.00 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (313.00) (252.00) (276.00) (285.00) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 545.00 547.00 663.00 415.00 ‡‡‡‡‡ — —
FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,419.00 1,590.00 1,630.00 1,962.00 — — —
Working Cap'
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8,913.00 8,760.00 8,880.00 8,644.00 — — —
Total Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8,207.00 8,067.00 8,205.00 8,070.00 — — —
Net Debt
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (892.00) (70.00) 472.00 752.00 — — —
Sh' Equity
— ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 8.48% 8.89% 6.87% 1.44% — — —
ROA
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.41% 9.82% 9.90% 5.84% — — —
ROIC
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (76.42%) (212.68%) 429.85% 30.56% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Organon & Co. (OGN), trading near multi-year lows in early 2026, presents a rare inflection point for value investors, underscored by robust insider buying in 2025—including CEO and CFO purchases—with no offsetting sells, a historically bullish signal for biotech spin-offs. Analyst targets imply a mean 22% upside, with highs reaching 62%, despite near-term risks from patent expirations and generics. Depressed valuations—PE at 3-4x, PS at 0.6x—scream undervaluation, backed by revenue stabilization post-2021 Merck spin-off, improving FCF per share (up 20% to $2.58), and deleveraging from a $8.2 billion debt overhang.

Fundamentals reveal resilience amid past headwinds: revenue bottomed after a 38% drop from 2017 peaks, now flat at ~$6.4 billion with efficiency gains (revenue per employee up 156%). Margins are rebounding—EBT up 17% YoY, ROE flipping positive at 4.3%—while historical analogs like Zoetis suggest 15-25% rebounds follow such productivity surges in pharma spin-offs.

Forward catalysts include Nexplanon extensions, biosimilar ramps, and FCF projected to surge 54% to $5.61 per share by 2027, with Monte Carlo models showing 55% odds of 20%+ upside. Yet conservatism lingers in flat revenue forecasts and margin risks, positioning OGN as a high-conviction mean-reversion play for patient strategists.

Read full commentary →

Organon & Co. (OGN) Latest News

News by impact score

Fine-tune

14 Sep

4 , 7:30 AM
Organon announced the US FDA accepted for review a supplemental New Drug Application for MIUDELLA, a hormone-free intrauterine device. FDA acceptance advances MIUDELLA toward potential approval and expands Organon's contraceptive portfolio with a differentiated product.

10 Sep

3 , 11:22 AM
Unexpected flaws in Cooper's earnings triggered a sharp stock price decline. Earnings shortfalls signal operational or competitive issues that may weigh on near-term results.

11 Aug

3 , 7:30 AM
Organon opens REMS program for MIUDELLA ahead of commercial availability. REMS opening for MIUDELLA advances product launch and supports future revenue streams.

31 Jul

3 , 11:00 AM
Organon & Co. (OGN) Q2 earnings are compared to analyst estimates with focus on key financial metrics performance. Q2 earnings versus estimates and key metrics can moderately influence near-term stock sentiment and valuation.

24 Jul

4 , 8:00 AM
Phase 3 pooled data analysis shows Organon’s VTAMA cream produces early consistent improvements in atopic dermatitis across pediatric age groups and adults. Positive Phase 3 data analysis bolsters VTAMA positioning in the large atopic dermatitis market and supports future revenue growth.

23 Jul

4 www.marketbeat.com, 11:07 AM
Organon & Co. shareholders approved the Sun Pharma merger deal. Merger clearance with Sun Pharma marks a major strategic shift likely to alter Organon operations and market trajectory.

30 Jun

4 , 9:08 AM
Organon & Co. launches MIUDELLA, positioning the product as a potential major growth driver in women’s health markets. MIUDELLA launch targets women’s health markets with potential to drive substantial revenue and shift company trajectory.

23 Jun

3 Business Wire, 5:30 AM
Organon Canada and Henlius launch BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection) as biosimilars to PROLIA and XGEVA to expand access to Denosumab treatments. Biosimilar launches in Canada provide market expansion opportunity with noticeable but regionally limited effects on overall performance.

22 Jun

4 Business Wire, 7:30 AM
Organon completes licensing agreement for MIUDELLA, Sebela Pharmaceuticals' hormone-free intrauterine device. Licensing deal adds novel hormone-free IUD to Organon's portfolio, likely enhancing competitive stance in contraception markets.

15 Jun

4 , 8:17 PM
TOFIDENCE gains expanded label approval covering CRS and COVID, prompting questions over effects on Organon (OGN) investment case and future performance. Expanded TOFIDENCE label directly affects Organon product portfolio, revenue outlook and investor positioning.

3 , 4:08 AM
Organon secures TOFIDENCE approval, prompting reassessment of OGN stock valuation and recovery potential. New product approval moderately strengthens pipeline and supports valuation recovery.

12 Jun

4 , 9:15 AM
Organon wins FDA approval to expand TOFIDENCE use in severe CRS and COVID-19. FDA expansion approval for TOFIDENCE opens new revenue streams in CRS and COVID-19 markets.

10 Jun

4 Business Wire, 7:30 AM
Organon secures US FDA approval expanding TOFIDENCE (tocilizumab-bavi) indications to Cytokine Release Syndrome and Pediatric COVID-19. Expanded FDA indications broaden TOFIDENCE revenue opportunities and usage.

25 May

3 Simply Wall St., 7:08 PM
Organon & Co. cleared its audit while new data shifts focus to company valuation and associated risks. Audit clearance reduces uncertainty and new data on valuation plus risks can moderately influence investor perception and near-term stock movement.

21 May

3 GlobeNewswire, 5:06 AM
Hanmi Pharmaceutical partners with Organon to export combination therapies to Southeast Asia. Export partnership expands Organon's market reach for therapies into Southeast Asia.

7 May

5 Simply Wall St., 8:12 AM
Sun Pharma's buyout of Organon & Co. (OGN) shifts investor focus to the deal's cash value and timing. Buyout by Sun Pharma fundamentally redefines Organon's independence, ownership, and long-term prospects.

1 May

4 Insider Monkey, 10:46 AM
Sun Pharma's major investment in specialty drug expansion triggers strong reactions from Organon (OGN) investors. Sun Pharma's aggressive expansion into specialty drugs intensifies competition and drives significant investor sentiment shifts for Organon.

30 Apr

4 Zacks, 10:00 AM
Organon (OGN) Q1 earnings key metrics compared to analyst estimates. Q1 earnings metrics versus estimates can significantly sway stock price, investor sentiment, and short-term trajectory.

4 Business Wire, 7:30 AM
Organon & Co. (OGN) reported financial results for the first quarter ended March 31, 2026. Quarterly earnings releases provide critical financial data that significantly sway stock performance and investor outlook.

3 StockStory, 6:10 PM
Organon (NYSE:OGN) missed Q1 CY2026 revenue estimates. Missing Q1 CY2026 revenue estimates indicates weaker-than-expected sales, moderately impacting financial performance and investor sentiment.

3 Zacks, 9:25 AM
Organon (OGN) Q1 earnings and revenues missed analyst estimates. Q1 earnings and revenue misses highlight weaker financial results, moderately impacting investor sentiment and short-term stock performance.

29 Apr

4 PR Newswire, 10:00 AM
European Commission approves Henlius and Organon's POHERDY® (pertuzumab), the first biosimilar to PERJETA® (pertuzumab) in Europe. EC approval of the first Perjeta biosimilar expands Organon's European oncology portfolio and revenue potential.

4 PR Newswire, 6:08 AM
European Commission approves Henlius and Organon's POHERDY® (pertuzumab), the first biosimilar to PERJETA (pertuzumab) in Europe. EC approval of the first Perjeta biosimilar enables Organon to enter Europe's high-value oncology market with potential for significant revenue growth.

4 Business Wire, 5:30 AM
The European Commission approved Henlius and Organon’s POHERDY® (pertuzumab), the first biosimilar to Roche’s PERJETA® (pertuzumab) in Europe. EC approval of Organon's first pertuzumab biosimilar in Europe enables major market entry, revenue growth, and competitive positioning in oncology.

3 Business Wire, 7:30 AM
Organon & Co. (OGN) cancels its first quarter earnings call. Cancellation signals potential issues with quarterly results, moderately impacting investor sentiment and short-term market performance.

28 Apr

4 www.pharmavoice.com, 4:00 AM
Biosimilars gaining traction in the US are increasing scrutiny on patent thickets, posing challenges for Organon & Co. (OGN). Biosimilar expansion and patent thicket scrutiny threaten Organon's drug exclusivity and revenue streams.

27 Apr

5 Insider Monkey, 10:16 PM
Organon & Co. (OGN) stock surges to 52-week high on announcement of $11.75-billion merger with Sun Pharma. The $11.75-billion merger with Sun Pharma is a transformative deal that fundamentally redefines Organon & Co.'s competitive position and long-term prospects.

5 www.fool.com, 5:54 PM
Organon & Co. (OGN) shares surged on April 27 after Sun Pharma agreed to acquire the company in an all-cash deal. Sun Pharma's all-cash acquisition fundamentally transforms Organon's ownership, operations, and long-term market position.

5 app.moby.co, 1:01 PM
Sun Pharma acquires Organon & Co. (OGN), positioning the Indian drugmaker among pharmaceutical industry giants. Acquisition by Sun Pharma ends Organon's independence and transforms its market trajectory.

4 Barrons.com, 2:07 PM
Organon & Co. (OGN) acquires Sun, riding the pharmaceutical M&A wave, with shares surging amid positive market reaction. Sun takeover marks a major strategic expansion for Organon in pharma M&A, poised to significantly boost growth and stock performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us